These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15541468)

  • 1. Gemtuzumab ozogamicin: a component of induction therapy in AML?
    Giles F
    Leuk Res; 2005 Jan; 29(1):1-2. PubMed ID: 15541468
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.
    Radsak MP; Salih HR; Sökler M; Kanz L; Denzlinger C
    Leukemia; 2002 Sep; 16(9):1870-1. PubMed ID: 12200709
    [No Abstract]   [Full Text] [Related]  

  • 3. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
    Amadori S; Suciu S; Stasi R; Willemze R; Mandelli F; Selleslag D; Denzlinger C; Muus P; Stauder R; Berneman Z; Pruijt J; Nobile F; Cassibba V; Marie JP; Beeldens F; Baila L; Vignetti M; de Witte T
    Leukemia; 2005 Oct; 19(10):1768-73. PubMed ID: 16079891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
    Löwenberg B; Beck J; Graux C; van Putten W; Schouten HC; Verdonck LF; Ferrant A; Sonneveld P; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; Breems D; de Muijnck H; Schaafsma R; Verhoef G; Döhner H; Gratwohl A; Pabst T; Ossenkoppele GJ; Maertens J; ; ;
    Blood; 2010 Apr; 115(13):2586-91. PubMed ID: 20103782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study.
    Leone G; Rutella S; Voso MT; Fianchi L; Scardocci A; Pagano L
    Haematologica; 2004 May; 89(5):634-6. PubMed ID: 15136240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.
    Walter RB; Raden BW; Thompson J; Flowers DA; Kiem HP; Bernstein ID; Linenberger ML
    Leukemia; 2004 Nov; 18(11):1914-7. PubMed ID: 15385942
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg).
    Sievers EL
    Blood Cells Mol Dis; 2003; 31(1):7-10. PubMed ID: 12850477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676).
    de Vetten MP; Jansen JH; van der Reijden BA; Berger MS; Zijlmans JM; Löwenberg B
    Br J Haematol; 2000 Oct; 111(1):277-9. PubMed ID: 11091212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
    Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
    Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
    Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
    Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
    [No Abstract]   [Full Text] [Related]  

  • 14. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.
    Fenton C; Perry CM
    Drugs; 2005; 65(16):2405-27. PubMed ID: 16266206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 17. Gemtuzumab for relapsed acute myeloid leukemia.
    Med Lett Drugs Ther; 2000 Jul; 42(1083):67-8. PubMed ID: 10908423
    [No Abstract]   [Full Text] [Related]  

  • 18. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
    Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
    Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
    [No Abstract]   [Full Text] [Related]  

  • 20. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.
    Linenberger ML; Hong T; Flowers D; Sievers EL; Gooley TA; Bennett JM; Berger MS; Leopold LH; Appelbaum FR; Bernstein ID
    Blood; 2001 Aug; 98(4):988-94. PubMed ID: 11493443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.